News | Magnetic Resonance Imaging (MRI) | September 20, 2021

Rice engineers find more efficient models to analyze contrast agents that find disease

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging.

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging. Illustration by Arjun Valiya Parambathu


September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to determine the health of a patient, can be improved, according to Rice University engineers who are refining models they first used to enhance oil and gas recovery.

The team led by Dilip Asthagiri and Philip Singer of the George R. Brown School of Engineering had studied how nuclear magnetic resonance tools, commonly used in the oil industry to characterize deposits underground, could be optimized through molecular dynamics simulations

“We addressed a lot of fundamental scientific questions there, and we wondered if there were other ways we could use these simulations,” Asthagiri said. 

“There are roughly 100 million MRIs taken worldwide every year, and about 40% of them use gadolinium-based contrast agents, but the way they model MRI response to these agents hasn’t changed significantly since the 1980s,” Singer said. “We thought it would be a good test bed for our ideas.”

The results of their research appear in the Royal Society of Chemistry journal Physical Chemistry Chemical Physics.

Their paper demonstrates how limiting the number of parameters in simulations has the potential to improve the analysis of gadolinium-based contrast agents and how effective they are at imaging for clinical diagnosis. Their goal is to make better and more customizable contrast agents.

Doctors use MRI devices to “see” the state of soft tissues inside the body, including the brain, by inducing magnetic moments in the hydrogen nuclei of ever-present water molecules to align along the magnetic field. The device detects bright spots when the aligned nuclei “relax” back to thermal equilibrium following an excitation, and the faster they relax, the brighter the contrast.

That’s where paramagnetic gadolinium-based contrast agents come in. “Gadolinium ions increase sensitivity and make the signal brighter by decreasing the T1 relaxation time of hydrogen nuclei,” Asthagiri said. “Our ultimate goal is to help the optimization and design of these agents.”

Typically, gadolinium is “chelated” -- surrounded by metal ions -- to make it less toxic. “The body doesn’t remove gadolinium by itself and needs to be chelated so the kidneys can get rid of it after a scan,” Singer said. “But chelation also slows the molecular rotation, and that creates better contrast in the MRI image.”

The researchers noted “chelate” comes from the Greek word for claw. “In this case, these claws grip the gadolinium to make it stable,” he said. “We hope our models help us design a stronger grip, which will make them safer while maximizing their ability to increase contrast.”

They acknowledged that gadolinium chelates, which revolutionized MRI testing when introduced in the late 1980s, have been controversial lately since it was discovered that patients with kidney impairment were unable to eliminate all of the toxins. “They’ve since worked out that if you have good kidney function, the benefits outweigh the potential risks,” Singer said.

The team is also adapting its models beyond interactions with water. “In biological systems, cells have other constituents like osmolytes and denaturants like urea, so we’re modeling gadolinium with these different environments to build toward a variety of applications,” Asthagiri said. 

Co-authors of the paper are Rice graduate students Arjun Valiya Parambathu, Thiago Pinheiro dos Santos and Yunke Liu; senior research scientist Lawrence Alemany; George Hirasaki, the A.J. Hartsook Professor Emeritus and a research professor; and Walter Chapman, the William W. Akers Professor of Chemical and Biomolecular Engineering. 

Vinegar Technologies LLC, Chevron Energy Technology, the Rice University Consortium on Processes in Porous Media, the Department of Energy Office of Science and the Texas Advanced Computing Center at the University of Texas at Austin supported the research. 

For more information: www.ride.edu

Related Content on Gadolinium Contrast Safety:

The Debate Over Gadolinium MRI Contrast Toxicity

VIDEO: Big Concerns Remain for MRI Gadolinium Contrast Safety — An interview with Emanuel Kanal, M.D.

FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients

VIDEO: Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Subtle Medical Receives FDA 510(k) Clearance for AI-powered SubtleMR

VIDEO: Managing Gadolinium Safety — Interview with Lawrence Tanenbaum, M.D.

Artificial Intelligence Processes Provide Solutions to Gadolinium Retention Concerns

MRI's Environmental Impact

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

Recent Developments in Contrast Media

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

European Medicines Agency Issues Update on Gadolinium Contrast Agents

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

FDA: No Harm in MRI Gadolinium Retention in the Brain

VIDEO: MRI Gadolinium Contrast Retention in the Brain

Gadolinium May Remain in Brain After Contrast MRI

Related Content

News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Time October 06, 2021
arrow
News | Women's Health

October 5, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients ...

Time October 05, 2021
arrow
News | Ultrasound Imaging

October 5, 2021 — Ultrasound experts urged the health care community to work to expand utilization of ultrasound ...

Time October 05, 2021
arrow
News | Radiology Business

September 27, 2021 — Esaote, an Italian company leader in the biomedical equipment sector – ultrasound, MRI and software ...

Time September 27, 2021
arrow
News | Cardiac Imaging

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by ...

Time September 23, 2021
arrow
News | Radiation Oncology

September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and ...

Time September 17, 2021
arrow
News | Radiopharmaceuticals and Tracers

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 17, 2021
arrow
News | Contrast Media Injectors

September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthcare ...

Time September 16, 2021
arrow
Subscribe Now